{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273321","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.545637+00:00","generated_at":"2026-05-16T22:49:49.680787+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"MannKind discontinues Phase 3 MNKD-101 trial for NTM lung disease after futility analysis","bullets":["Discontinuation based on interim analysis of first 46 participants; none showed sputum culture conversion.","DSMB agreed with decision due to futility; no safety issues identified in any DSMB meetings.","Company will investigate outcome and focus on advancing MNKD-102 dry powder formulation toward Phase 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273321","json":"https://secwatch.observer/filing/0001193125-25-273321.json","markdown":"https://secwatch.observer/filing/0001193125-25-273321.md","text":"https://secwatch.observer/filing/0001193125-25-273321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312525273321/0001193125-25-273321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312525273321/d25083d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:49:49.680787+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001193125-26-252718","ticker":"QMCO","company_name":"QUANTUM CORP /DE/","filed_at":"2026-06-02T14:41:23+00:00","headline":"Quantum raises $100M equity, converts all convertible notes to equity; Q4 revenue above guidance","event_type":"other_material","sec_items":["1.01","2.02","2.03","3.02","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252718","json":"https://secwatch.observer/filing/0001193125-26-252718.json","markdown":"https://secwatch.observer/filing/0001193125-26-252718.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/709283/000119312526252718/0001193125-26-252718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/709283/000119312526252718/d35173d8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026761","ticker":"CELC","company_name":"Celcuity Inc.","filed_at":"2026-06-02T12:10:25+00:00","headline":"Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026761","json":"https://secwatch.observer/filing/0001493152-26-026761.json","markdown":"https://secwatch.observer/filing/0001493152-26-026761.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226026761/0001493152-26-026761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226026761/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001750155-26-000080","ticker":"CWBHF","company_name":"Charlotte's Web Holdings, Inc.","filed_at":"2026-06-01T21:13:23+00:00","headline":"Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment","event_type":"other_material","sec_items":["5.02","5.07","8.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001750155-26-000080","json":"https://secwatch.observer/filing/0001750155-26-000080.json","markdown":"https://secwatch.observer/filing/0001750155-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750155/000175015526000080/0001750155-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750155/000175015526000080/cweb-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251394","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-06-01T20:05:16+00:00","headline":"Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251394","json":"https://secwatch.observer/filing/0001193125-26-251394.json","markdown":"https://secwatch.observer/filing/0001193125-26-251394.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/0001193125-26-251394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001477932-26-003548","ticker":null,"company_name":"CORNER GROWTH ACQUISITION CORP. 2","filed_at":"2026-06-01T20:00:34+00:00","headline":"Corner Growth Acquisition Corp. 2 to liquidate and dissolve after failing to complete business combination","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-003548","json":"https://secwatch.observer/filing/0001477932-26-003548.json","markdown":"https://secwatch.observer/filing/0001477932-26-003548.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847513/000147793226003548/0001477932-26-003548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847513/000147793226003548/corner_8k.htm"},"side_by_side_evidence":null},{"accession":"0001477932-26-003547","ticker":null,"company_name":"Corner Growth Acquisition Corp.","filed_at":"2026-06-01T20:00:22+00:00","headline":"Corner Growth Acquisition Corp. to liquidate; will redeem public shares","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-003547","json":"https://secwatch.observer/filing/0001477932-26-003547.json","markdown":"https://secwatch.observer/filing/0001477932-26-003547.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829953/000147793226003547/0001477932-26-003547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829953/000147793226003547/cgac_8k.htm"},"side_by_side_evidence":null},{"accession":"0001628280-26-039297","ticker":"GPRO","company_name":"GoPro, Inc.","filed_at":"2026-06-01T13:12:22+00:00","headline":"GoPro refiles financials with going-concern warning; potential defaults on debt","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039297","json":"https://secwatch.observer/filing/0001628280-26-039297.json","markdown":"https://secwatch.observer/filing/0001628280-26-039297.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500435/000162828026039297/0001628280-26-039297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500435/000162828026039297/gpro-20260601.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}